The United States is currently experiencing a shortage of more than a dozen cancer medications, including Cisplatin, which the World Health Organization characterizes as an essential part of basic health care. Prescribed for 10 to 20 percent of all cancer patients, the shortage of Cisplatin, which Johns Hopkins School of Medicine’s Dr. Amanda Fader calls “the chemotherapy backbone,” is affecting hundreds of thousands of patients across the country. To address the shortage, the U.S. Food and Drug Administration (FDA) has authorized the temporary importation of an unapproved version of Cisplatin, as well as Carboplatin, from Qilu Pharmaceutical, located in communist China.

While it is unclear exactly why the FDA chose Qilu Pharmaceutical, given the underhanded and deceitful actions of the agency during the pandemic, the choice is worth exploring. Qilu Pharmaceutical was founded in 1958 in Jinan as a Chinese state-owned company. Yet, in December 2021, Pennsylvania-based Arbutus Biopharma Corporation—the company that holds ownership of the essential lipid nanoparticle (LNP) delivery technology used in the gene-damaging mRNA COVID-19 jabs—and Qilu Pharmaceutical announced they had entered into an exclusive licensing agreement and strategic partnership to develop and commercialize a cure for people with chronic hepatitis B virus (HBV) infection.

Interestingly, in early 2017, a British Columbia Supreme Court Justice granted Arbutus a pre-trial injunction stopping Acuitas (another Canadian-based, small company) from sublicensing Arbutus’ LNP delivery technology through at least October of that year. The ruling caused significant issues for Moderna Therapeutics, which, at the time—with $1 billion in cash, a large pipeline, and numerous deals and partnerships—was quietly working with DARPA on engineering mRNA to “turn patient’s cells into drug-making factories” when injected, using Arbutus’ LNP technology that it had sublicensed from Acuitas. Fast forward to today, and Arbutus, which has been awarded many patents related to its LNP delivery technologies, is still entangled in COVID-19 vaccine patent lawsuits against both Moderna and Pfizer, with Moderna chalking up a recent win in a separate case.

Arbutus—which up until 2015 was called Tekmira, based in Canada, and had received $50 million from Bill Gates for Ebola therapies—doesn’t appear to be involved in Qilu’s distribution of Cisplatin vials in the United States, which the FDA authorized for distribution on May 24, 2023. Instead, Toronto-based Apotex will distribute the drugs. The platinum-based Cisplatin is widely used to treat testicular, lung, bladder, cervical, gastric, breast, head and neck cancers, and ovarian cancers, among other disease states. Though highly toxic, the drug blocks cell division in tumors in low doses. According to Cancer.gov, Cisplatin’s cure rate against testicular cancer is more than 90 percent. Dr. Bruce Chabner, former director of the National Cancer Institute’s (NCI) Division of Cancer Treatment and now director of clinical research at the Massachusetts General Hospital Cancer Center, said of the drug’s capabilities:

“The patients cured by these regimens and those that have benefited from this therapy number in the millions. It would be frightening to imagine the current status of cancer treatment without this essential drug.”

Moving on, with the curious partnership between Qilu and Arbutus aside, according to mainstream news reports, the national shortage of Cisplatin began in February after India-based Intas Pharmaceuticals decided to temporarily halt production for the U.S. market. Its decision came after FDA inspections from November 22 through December 2, 2022, that discovered a “cascade of failure” in Intas’ quality control unit. The FDA’s Form 483 detailing its inspection of Intas is reminiscent of Brook Jackson’s experience with Ventavia and Pfizer’s shoddy COVID-19 vaccine trial that preceded the FDA’s emergency use authorization. Yet, unlike that experience, which cast the FDA in a bad light, the agency wasted no time detailing the “objectionable conditions” at the facility, including lapses in record-keeping including shredded documents, poorly defined procedures, controls, and issues about microbial contamination risk and environmental monitoring, among other problems.

The FDA recognizes the importance of a stable, safe supply of critical drugs used in oncology, especially those used in potentially curative or life-extending situations.

— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023

After an inspectional slowdown blamed on COVID-19 travel restrictions, the FDA has started to dish out inspectional write-ups at a steady clip, including to Intas Pharmaceuticals. If the company was truly shredding documents and hiding evidence, then kudos to the FDA for correctly doing its job. Still, thanks to COVID-19 and the scandals it has exposed, a massive spotlight has been shined on Big Pharma and the government agencies tasked with protecting the health of American citizens, including the FDA. Thus, it seems fitting to be suspicious of the extensive web of deceit that may lie beneath the surface of the FDA’s decisions. In the “Shortage Reason” section on its website for Cisplatin, the agency overwhelmingly notes “demand increase for the drug,” not a “manufacturing issue” or similar—nothing to see here. Move on.

What is the real motive behind the FDA’s actions involving platinum-based Cisplatin, Qilu, and dangerous LNP technology creator Arbutus—a company which is also heavily focused on coronaviruses with ties to Bill Gates? We may never know, but Dr. Ryan Cole MD, pathologist, was one of the very first doctors to report the significant jump in cancers—including the ones treated with Cisplatin—he began witnessing within months after the deadly COVID-19 vaccine rollout. And it is not just the vaccines themselves but also the LNPs (developed by Arbutus) used in Pfizer and Moderna’s shots. With the billions reaped by Big Pharma during the pandemic aided by the FDA (the Biden administration and other federal agencies), it is a safe bet there is more to the story than we are being told.